Key result
The GIRK channel blocker tertiapin-Q significantly depolarized pulmonary vein cardiomyocytes from -74.1 mV to -57.4 mV (p<0.001) and abolished action potentials, offering a targeted approach to inhibit ectopic activity.
Why the study?
Pulmonary veins are the main source of ectopy triggering AF, prompting investigation into the roles of GIRK channels in rat pulmonary veins and left atrium.
Does the GIRK channel blocker tertiapin-Q selectively inhibit excitability in rat pulmonary veins compared to the left atrium?
Does the GIRK channel blocker tertiapin-Q selectively inhibit excitability in rat pulmonary veins compared to the left atrium?
Blockade of constitutively active GIRK channels selectively abolishes action potentials in pulmonary veins, offering a potential pharmacological target for treating atrial fibrillation.
Pulmonary veins (PV) are the main source of ectopy, triggering atrial fibrillation. This study investigated the roles of G protein-coupled inwardly rectifying potassium (GIRK) channels in the PV and the left atrium (LA) of the rat. Simultaneous intracellular microelectrode recording from the LA and the PV of the rat found that in the presence or absence of acetylcholine, the GIRK channel blocker tertiapin-Q induced AP duration elongation in the LA and the loss of over-shooting AP in the PV, suggesting the presence of constitutively active GIRK channels in these tissues. Patch-clamp recordings from isolated myocytes showed that tertiapin-Q inhibited a basal inwardly rectified background current in PV cells with little effect in LA cells. Experiments with ROMK1 and KCa1.1 channel blockers ruled out the possibility of an off-target effect. Western blot showed that GIRK4 subunit expression was greater in PV cardiomyocytes, which may explain the differences observed between PV and LA in response to tertiapin-Q. In conclusion, GIRK channels blockade abolishes AP only in the PV, providing a molecular target to induce electrical disconnection of the PV from the LA.
No takes yet. Share an insight, caveat, or question.
Findlay et al. (2023) studied Atrial fibrillation pathophysiology (pulmonary vein ectopic activity). Tertiapin-Q (TQ) vs. Baseline (absence of Tertiapin-Q) was evaluated on Pulmonary vein (PV) resting membrane potential in the absence of acetylcholine (p=<0.001). The GIRK channel blocker tertiapin-Q significantly depolarized pulmonary vein cardiomyocytes from -74.1 mV to -57.4 mV (p<0.001) and abolished action potentials, offering a targeted approach to inhibit ectopic activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: